Therapeutic trials > phone (734) 764-DERM(3376)
Volunteers Are Needed!
For information about Dermatology’s active therapeutic trials search for "skin conditions" at the UM Clinical Studies website (www.umclinicalstudies.org). Click on the study IRB# for detailed eligibility requirements.
Potential new drugs or devices to better treat skin diseases and conditions require rigorous testing while conforming to strict regulatory requirements.
The Clinical Research Unit (CRU) works with pharmaceutical companies, ranging in size from small to multinational, to develop safer and more effective treatments for patients. In many instances, we assist these companies in the design of clinical protocols, as well as in the execution of the studies.
Psoriasis - Our CRU has a long and outstanding history of involvement with psoriasis research. Past work includes a pivotal study demonstrating the effectiveness of cyclosporine (CsA) treatment in psoriasis, followed by delineation of its mechanism of action. Also, the first psoriasis patient to receive biologic drug (CTLA-4Ig) was a UMHS Dermatology patient. The successful demonstration of this biologic drug’s efficacy unleashed the explosive development of other protein-based agents in psoriasis. We continue to lead the scientific community with our therapeutic trials in psoriasis.
Photoaging and aging skin - Dermatology’s CRU was instrumental to the development of the first topical agents approved for the treatment of photoaged skin. The first vehicle-controlled study demonstrating the efficacy of topical retinoic acid in photoaging was conducted in the CRU, and we were the lead center in the pivotal study for tazarotene in photoaging.
Other skin conditions - In addition to psoriasis and photoaging, we frequently study atopic dermatitis, rosacea, acne, and actinic keratoses. Even non-surgical approaches for the treatment of skin cancers have been studied in the CRU.
Back to Clinical Research